MX2 has thus been capable of antitumour effects superior to those of adriamycin (ADM) against several murine and human tumour cell lines, even against multidrug-resistance tumour cell lines that overexpress P-glycoprotein (Watanabe et al, 1991). The gene discussed is ABCB1; the disease is neoplasm.